<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03695029</url>
  </required_header>
  <id_info>
    <org_study_id>201010078M</org_study_id>
    <nct_id>NCT03695029</nct_id>
  </id_info>
  <brief_title>Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus</brief_title>
  <official_title>Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy of using antiviral therapy in third trimester of pregnancy to
      reduce mother-to-infant HBV transmission, and to access the safety of such treatment for
      mothers and infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-centered study conducted in 12-16 collaborative hospitals in Taiwan, using
      tenofovir as antiviral therapy to reduce mother-to-infant transmission. The study group
      recruited pregnant women at 2nd to 3rd trimester receive tenofovir disoproxil fumurate (TDF)
      2011-2018, June, and receive tenofovir alafenamide (TAF) 2018-2021. Control group did not
      receive antiviral treatment. Both group receive mother and infant follow-up up to 12 months
      after delivery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 29, 2010</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Child HBsAg 6 mo</measure>
    <time_frame>6 months after delivery</time_frame>
    <description>Serum status of HBsAg of the infants at 6 months old</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Child HBsAg 12 mo</measure>
    <time_frame>12 months after delivery</time_frame>
    <description>Serum status of HBsAg of the infants at 12 months old</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal ALT elevation</measure>
    <time_frame>6 months after delivery</time_frame>
    <description>Rate of postpartum maternal ALT elevation above 2X upper limit of normal within 6 months after delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal HBeAg-seroconverion</measure>
    <time_frame>12 months after delivery</time_frame>
    <description>HBeAg-seroconversion rate within 12 months after delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal renal</measure>
    <time_frame>6 and 12 months post delivery</time_frame>
    <description>Maternal serum creatinine (mg/dL) at 6 and 12 months post delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Materna bone marker</measure>
    <time_frame>6 and 12 months post delivery</time_frame>
    <description>Maternal bone alkaline phosphatase (ug/L) at 6 and 12 months post delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's growth</measure>
    <time_frame>6 and 12 months after birth</time_frame>
    <description>Children's growth: height (cm) in Z score at 6 and 12 months after birth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Children's growth</measure>
    <time_frame>6 and 12 months after birth</time_frame>
    <description>Children's growth: weight (kg) in Z score at 6 and 12 months after birth</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hepatitis B Virus Infection</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>control group receive no drug, only follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Alafenamide</intervention_name>
    <description>Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Women aged 20-45 years in 28 to 32 weeks of pregnancy

          -  Positive HBsAg and HBeAg

          -  Serum viral load above 6 log10 IU/mL

        Exclusion criteria:

          -  Major systemic disease of the mother or fetus

          -  Positive anti-HIV or anti-HCV

          -  Under treatment of antiviral therapy

          -  Pregnant woman whose ultrasonographic examination reveals congenital anomaly of the
             fetus

          -  Pregnant woman whose amniocentesis reveals any genetic abnormality
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Pregnant women</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mei-Hwei Chang</last_name>
    <phone>+886-2-23123456</phone>
    <phone_ext>71701</phone_ext>
    <email>changmh@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivy Chiou</last_name>
      <phone>+886-2-23123456</phone>
      <phone_ext>71737</phone_ext>
      <email>ivyntuh@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 20, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Herpesviridae Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

